401 related articles for article (PubMed ID: 15788977)
21. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
Schächinger V; Zeiher AM
Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Otterstad JE; Brosstad F
Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
[No Abstract] [Full Text] [Related]
23. Antiplatelet agents and arterial thrombosis.
Billett HH
Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
[TBL] [Abstract][Full Text] [Related]
24. Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.
Levine GN; Berger PB; Cohen DJ; Maree AO; Rosenfield K; Wiggins BS; Spinler SA
Pharmacotherapy; 2006 Nov; 26(11):1537-56. PubMed ID: 17064198
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty.
Barry WL; Sarembock IJ
Cardiol Clin; 1994 Aug; 12(3):517-35. PubMed ID: 7805084
[TBL] [Abstract][Full Text] [Related]
26. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Spinler SA
Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Rodgers JE; Steinhubl SR
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):507-21. PubMed ID: 15030250
[TBL] [Abstract][Full Text] [Related]
28. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
29. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
[TBL] [Abstract][Full Text] [Related]
30. Oral antiplatelet therapy for percutaneous coronary revascularization.
Hamdalla H; Steinhubl SR
Catheter Cardiovasc Interv; 2007 Apr; 69(5):637-42. PubMed ID: 17351930
[TBL] [Abstract][Full Text] [Related]
31. Enoxaparin and percutaneous coronary intervention: a Canadian perspective.
Fitchett D; Welsh R; Langer A; Goodman S
Can J Cardiol; 2005 May; 21(6):501-7. PubMed ID: 15917879
[TBL] [Abstract][Full Text] [Related]
32. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.
Rothman MT
Nat Clin Pract Cardiovasc Med; 2005 Sep; 2(9):465-74. PubMed ID: 16265587
[TBL] [Abstract][Full Text] [Related]
33. Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
Steinhubl SR
Rev Cardiovasc Med; 2006; 7 Suppl 4():S12-9. PubMed ID: 17224886
[TBL] [Abstract][Full Text] [Related]
34. Clopidogrel: an updated and comprehensive review.
Fox KA; Chelliah R
Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):621-31. PubMed ID: 17696811
[TBL] [Abstract][Full Text] [Related]
35. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
[TBL] [Abstract][Full Text] [Related]
36. Evolving management of ST-segment elevation myocardial infarction: update on recent data.
Cannon CP
Am J Cardiol; 2006 Dec; 98(12A):10Q-21Q. PubMed ID: 17169625
[TBL] [Abstract][Full Text] [Related]
37. Anti-thrombotic and anticoagulant treatment in interventional cardiology.
Mahanonda N
J Med Assoc Thai; 1998 Jan; 81(1):42-6. PubMed ID: 9470321
[TBL] [Abstract][Full Text] [Related]
38. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Rubboli A; Halperin JL
Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
[No Abstract] [Full Text] [Related]
39. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Roldán V; Marín F
Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
[No Abstract] [Full Text] [Related]
40. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Ferguson J
J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
